Journey Medical Corp (DERM) stock
DERMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3024% below fair value
$4.33−0.06 (-1.37%)
Close on Nov 13, 2026Market cap $122.21MP/E –Yield –
Journey Medical r&d expenses
Research and development expenses are spending on new products and technology.
Journey Medical's R&D Expenses for the twelve months ending Dec 31, 2025 was $480.00K, down 95.1% year over year. For fiscal 2025 it was $480.00K, down 95.1% from the year before. The highest annual figure on record is $10.94M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $480.00K | -95.1% |
| FY2024 | Dec 31, 2024 | $9.86M | +30.7% |
| FY2023 | Dec 31, 2023 | $7.54M | -31.1% |
| FY2022 | Dec 31, 2022 | $10.94M | +299.5% |
| FY2021 | Dec 31, 2021 | $2.74M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $51.00K | – |
| Q2 FY2026 | Jun 30, 2026 | $54.00K | +38.5% |
| Q4 FY2025 | Dec 31, 2025 | $154.00K | -29.4% |
| Q3 FY2025 | Sep 30, 2025 | $287.00K | -65.9% |
| Q2 FY2025 | Jun 30, 2025 | $0 | -100.0% |
| Q1 FY2025 | Mar 31, 2025 | $39.00K | -99.5% |
| Q4 FY2024 | Dec 31, 2024 | $218.00K | -85.5% |
| Q3 FY2024 | Sep 30, 2024 | $842.00K | -62.2% |
| Q2 FY2024 | Jun 30, 2024 | $913.00K | -78.5% |
| Q1 FY2024 | Mar 31, 2024 | $7.88M | +180.4% |
| Q4 FY2023 | Dec 31, 2023 | $1.51M | -42.3% |
| Q3 FY2023 | Sep 30, 2023 | $2.23M | +76.1% |
| Q4 FY2022 | Dec 31, 2022 | $4.26M | +113.7% |
| Q3 FY2022 | Sep 30, 2022 | $2.81M | +291.6% |
| Q2 FY2022 | Jun 30, 2022 | $2.61M | +8896.6% |
| Q1 FY2022 | Mar 31, 2022 | $1.27M | – |
| Q4 FY2021 | Dec 31, 2021 | $1.99M | – |
| Q3 FY2021 | Sep 30, 2021 | $718.00K | – |
| Q2 FY2021 | Jun 30, 2021 | $29.00K | – |
See a number that looks wrong?